High Aneuploidy Scores Linked to Poor Immunotherapy Outcomes in Cancer
Findings from a recent biomarker analysis of the phase 3 AtTEnd trial revealed that high whole-exome sequencing (WES) aneuploidy scores (W-AS) are associated with poorer outcomes when adding atezolizumab (Tecentriq)…